Top

Global Colorectal Cancer Drugs Market 2015-2019

Category : Pharmaceuticals  | Published Date : Jun-2015 | Pages : 125
enquire GET DISCOUNT
About Colorectal Cancer 

Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

Technavio's analysts forecast the global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer. 

Based on the type of molecule, the market is grouped into two categories:

• Biologics
• Small molecules

Based on the route of administration, the market is grouped into two categories:

• Oral
• Parenteral

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions: 

• Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
• EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population

• APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. 

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio's report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas 
• APAC
• EMEA 

Key Vendors
• Amgen
• Bayer
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck Serono

Other Prominent Vendors 
• Accord Healthcare
• Advenchen Laboratories
• Aeterna Zentaris
• AstraZeneca
• Bavarian Nordic
• Biothera
• Boehringer Ingelheim
• Daiichi Sankyo
• Debiopharm
• Eisai
• Eli Lilly
• Immodulon Therapeutics
• Mologen
• Mylan
• Nektar Therapeutics
• Oncothyreon
• Otsuka Pharmaceutical
• Precision Biologics
• Sun Pharmaceutical
• Symphogen
• Taiho
• Takeda
• Teva
• ThromboGenics
• Xbiotech
• Yakult Honsha 

Market Driver
• Increase in population of patients
• For a full, detailed list, view our report

Market Challenge
• Loss of patent exclusivity
• For a full, detailed list, view our report

Market Trend
• Dominance of biologics
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.5 Staging
06.5.1 Staging: Colon Cancer
06.5.2 Staging: Rectal Cancer
06.6 Management
06.7 Economic Burden
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.2.1 Colorectal Cancer Drugs Market in US
07.2.2 Colorectal Cancer Drugs Market in Germany
07.2.3 Colorectal Cancer Drugs Market in Spain
07.2.4 Colorectal Cancer Drugs Market in Japan
07.2.5 Colorectal Cancer Drugs Market in China
07.3 Five Forces Analysis
08. Market Segmentation by Type of Molecules
08.1 Small molecules
08.2 Biologics
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
10. Geographical Segmentation
10.1 Colorectal Cancer Drugs Market in Americas
10.1.1 Market Size and Forecast
10.2 Colorectal Cancer Drugs Market in EMEA
10.2.1 Market Size and Forecast
10.3 Colorectal Cancer Drugs Market in APAC
10.3.1 Market Size and Forecast
11. Key Leading Countries
11.1 US
11.2 Japan
11.3 Germany
11.4 Spain
11.5 China
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Competitive Assessment of Top Drugs for Colorectal Cancer
19.2.2 F. Hoffmann-La Roche
19.2.3 Merck Serono
19.2.4 Bristol-Myers Squibb
19.2.5 Amgen
19.2.6 Sanofi
19.2.7 Bayer
19.3 Other and Future Prominent Vendors
20. Key Takeaways
21. Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Bayer
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Business segmentation by revenue 2014
21.2.4 Business segmentation by revenue 2013 and 2014
21.2.5 Geographical segmentation by revenue 2014
21.2.6 Business strategy
21.2.7 Recent developments
21.2.8 SWOT analysis
21.3 Bristol-Myers Squibb Co.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Product Offerings
21.3.4 Revenue by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Merck Serono
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Geographical Segmentation by Revenue 2013
21.5.4 Business Strategy
21.5.5 Recent Developments
21.5.6 SWOT Analysis
21.6 Sanofi SA
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Drivers and Challenges of the Global Colorectal Cancer Drugs Market
Exhibit 3: Diagnosis of Colorectal Cancer
Exhibit 4: Management of Colorectal Cancer
Exhibit 5: A Snapshot of the Economic Burden of the Global Colorectal Cancer Drugs Market
Exhibit 6: Snapshot of the Global Colorectal Cancer Drugs Market
Exhibit 7: Global Colorectal Cancer Drugs Market 2014-2019 ($ millions)
Exhibit 8: Colorectal Cancer Drugs Market in US 2014-2019 ($ millions)
Exhibit 9: Colorectal Cancer Drugs Market in Germany 2014-2019 ($ millions)
Exhibit 10: Colorectal Cancer Drugs Market in Spain 2014-2019 ($ millions)
Exhibit 11: Colorectal Cancer Drugs Market in Japan 2014-2019 ($ millions)
Exhibit 12: Colorectal Cancer Drugs Market in China 2014-2019 ($ millions)
Exhibit 13: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules
Exhibit 14: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules, 2014
Exhibit 15: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration
Exhibit 16: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration, 2014
Exhibit 17: Global Colorectal Cancer Drugs Market by Geographical Segmentation 2014
Exhibit 18: Colorectal Cancer Drugs Market in Americas 2014-2019 ($ millions)
Exhibit 19: Colorectal Cancer Drugs Market in EMEA 2014-2019 ($ millions)
Exhibit 20: Colorectal Cancer Drugs Market in APAC 2014-2019 ($ millions)
Exhibit 21:
Exhibit 22: Drivers of the Global Colorectal Cancer Drugs Market
Exhibit 23: Challenges of the Global Colorectal Cancer Drugs Market
Exhibit 24: Trends of the Global Colorectal Cancer Drugs Market
Exhibit 25: YoY Growth Rate of the Major Colorectal Cancer Drugs 2010-2014 ($ millions)
Exhibit 26: F. Hoffmann-La Roche: Product Portfolio
Exhibit 27: Avastin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 28: Avastin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 29: YoY Revenues and Growth Rate of Avastin in the US 2010-2014 ($ millions)
Exhibit 30: YoY Revenues and Growth Rate of Avastin in Europe 2010-2014 ($ millions)
Exhibit 31: YoY Revenues and Growth Rate of Avastin in Japan 2010-2014 ($ millions)
Exhibit 32: YoY International Revenues and Growth Rate of Avastin 2010-2014 (Except US, Europe, Japan) ($ millions)
Exhibit 33: Xeloda: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 34: Xeloda: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 35: YoY Revenues and Growth Rate of Xeloda in the US ($ millions)
Exhibit 36: YoY Revenues and Growth Rate of Xeloda in Europe 2010-2014 ($ millions)
Exhibit 37: YoY Revenues and Growth Rate of Xeloda in Japan 2010-2014 ($ millions)
Exhibit 38: YoY International Revenues and Growth Rate of Xeloda (Except US, Europe, Japan) ($ millions)
Exhibit 39: Merck Serono: Product Portfolio
Exhibit 40: Erbitux: Revenue and YoY Growth Rate except US and Canada 2010-2014 ($ millions)
Exhibit 41: Erbitux: Region-wise Revenues 2012-2014 ($ millions)
Exhibit 42: Erbitux: Revenue and YoY Growth Rate in Europe 2012-2014 ($ millions)
Exhibit 43: Erbitux: Revenue and YoY Growth Rate in Emerging Markets 2012-2014 ($ millions)
Exhibit 44: Erbitux: Revenue and YoY Growth Rate in ROW 2012-2014 ($ millions)
Exhibit 45: Bristol-Myers Squibb: Product Portfolio
Exhibit 46: Erbitux: Revenue and YoY Growth Rate in US and Canada 2010-2014 ($ millions)
Exhibit 47: Amgen: Product Portfolio
Exhibit 50: Vectibix: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 51: Vectibix: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 52: Sanofi: Product Portfolio
Exhibit 53: Eloxatin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 54: Eloxatin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 55: YoY Revenues and Growth Rate of Eloxatin in the US ($ millions)
Exhibit 56: YoY Revenues and Growth Rate of Eloxatin in Europe ($ millions)
Exhibit 57: YoY Revenues and Growth Rate of Eloxatin in Emerging Markets ($ millions)
Exhibit 58: YoY Revenues and Growth Rate of Eloxatin in ROW 2010-2014 ($ millions)
Exhibit 59: Zaltrap: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
Exhibit 60: Zaltrap: Region-wise Revenue 2013-2014 ($ millions)
Exhibit 61: Bayer: Product Portfolio
Exhibit 62: Stivarga: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
Exhibit 63: Key Takeaways: Global Colorectal Cancer Drugs Market 2015-2019
Exhibit 64: Amgen: Business Segmentation by Revenue 2013
Exhibit 65: Amgen: Product Portfolio by Revenue 2013
Exhibit 66: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 67: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 68: Bayer: Business segmentation by revenue 2014
Exhibit 69: Bayer: Business segmentation by revenue 2013 and 2014 (US$ billion)
Exhibit 70: Bayer: Geographical segmentation by revenue 2014
Exhibit 71: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 72: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 73: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 74: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 75: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 76: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 77: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 78: Sanofi SA: Business Segmentation
Exhibit 79: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 80: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 81: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 3000
Five User: US $ 3500
Site User: US $ 4500
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top